Tecan and Dynal Begin Magnetic Partnership
News Oct 27, 2005
Tecan and Dynal (a subsidiary of Invitrogen Corporation) have joined forces, combining Tecan's Freedom EVO® automated liquid handling platforms with Dynal Biotech's Dynabeads® magnetic bead technology for isolation of any biological starting material, including mRNA, DNA and recombinant proteins.
The flexibility of the Freedom EVO series of platforms offering a variety of liquid handling and robotic arm options complements the Dynabeads, whose compatibility with a wide variety of molecular tags makes it possible to isolate and concentrate cells, DNA, mRNA, organelles and proteins from the difficult sources.
Tecan and Dynal Biotech have jointly developed several application-specific protocols, including the recombinant protein purification procedure, which combines Tecan's Te-MagS magnetic separation technology with Dynabeads' TALON™ system to isolate histidine affinity-tagged proteins from lysed cells.
The Dynabeads mRNA Direct™ Kit rapidly isolates pure, intact mRNA from lysates of biological tissues using a Freedom EVO platform with a Tecan Te-MO 96-channel pipetting module and robotic manipulator arm.
Dynabeads are also effective with this equipment in the Sequencing Clean-Up system, for consistent, high quality purification of DNA sequencing reactions.
Whatever the application, multiple batches of Dynabead-isolated samples can be processed with Tecan's Freedom EVO platforms without any user intervention, making higher throughput easy to achieve.
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018